Endocapillary Hypercellularity Levels Are Associated with Early Complete Remission in Children with Class IV Lupus Nephritis As the Initial Presentation of SLE

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2022 Aug 25

PMID 36008770

Authors

Chunzhen Li

Yanan Han

Lili Zhang

Zhiguo Chen

Mei Jin

Suzhen Sun

Affiliations

Soon will be listed here.

Abstract

Background: Endocapillary hypercellularity (ECHC) is commonly seen in class IV lupus nephritis (LN), the most common and severe LN in children. Factors influencing early complete remission (CR) in pediatric class IV LN have been poorly described. We investigated the relationship between ECHC levels and early CR in pediatric class IV LN.

Methods: Patients with newly, simultaneously diagnosed systemic lupus erythematosus (SLE) and class IV LN by renal biopsy from 2012 to 2021 were studied. In this retrospective study, two pathologists who were blind to clinical information reviewed all pathological data retrospectively and classified glomerular lesions according to the revised criteria of the International Society of Nephrology and the Renal Pathology Society (ISN/RPS). The demographics, baseline clinical characteristics, laboratory parameters, renal histopathological findings, treatment regimen and CR at 6 months after immunosuppressive therapy were analyzed. ECHC was categorized as: > 50% (group A), 25-50% (group B) and < 25% (group C). CR was defined as absence of clinical symptoms, 24-hour urinary protein < 0.15 g, and normal levels of serum creatinine and albumin.

Results: Sixty-four patients were identified: 23, 15 and 26 in groups A, B and C, respectively. Group A had significantly higher levels of D-dimer, urine protein, and SLE disease activity index (SLEDAI) than groups B and C. Group C had a markedly higher estimated glomerular filtration rate (eGFR) than groups A and B. A substantially greater proportion of patients in group A had glomerular microthrombi and basement membrane thickening than in groups B and C. At 6 months post treatment, CR was achieved in 19 (82.6%), 5 (33.3%) and 11 (42.3%) in groups A, B and C, respectively (p < 0.05, group A vs groups B and C). Multiple logistic regression analysis revealed that ECHC and urine protein levels were significantly associated with CR.

Conclusion: ECHC and urine protein levels may be valuable biomarkers for predicting early CR in pediatric class IV LN.

Citing Articles

Long-term outcomes and predictive factors of achieving low disease activity status in childhood systemic lupus erythematosus: a Chinese bicentric retrospective registered study.

Yu X, Deng J, Chen Q, Qiu S, Jiang C, Wu Y Front Immunol. 2024; 15:1369969.

PMID: 38915395 PMC: 11194373. DOI: 10.3389/fimmu.2024.1369969.

References

Suhlrie A, Hennies I, Gellermann J, Buscher A, Hoyer P, Waldegger S . Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol. 2020; 35(7):1235-1246. DOI: 10.1007/s00467-020-04501-x. View

Aragon E, Chan Y, Ng K, Lau Y, Tan P, Yap H . Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus. 2010; 19(8):965-73. DOI: 10.1177/0961203310366855. View

Almaani S, Prokopec S, Zhang J, Yu L, Avila-Casado C, Wither J . Rethinking Lupus Nephritis Classification on a Molecular Level. J Clin Med. 2019; 8(10). PMC: 6832959. DOI: 10.3390/jcm8101524. View

Heinlen L, McClain M, Merrill J, Akbarali Y, Edgerton C, Harley J . Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007; 56(7):2344-51. DOI: 10.1002/art.22665. View

Lau K, Jones D, Hastings M, Gaber L, Ault B . Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol. 2006; 21(5):655-62. DOI: 10.1007/s00467-006-0060-3. View

Hari P, Bagga A, Mahajan P, Dinda A . Outcome of lupus nephritis in Indian children. Lupus. 2009; 18(4):348-54. DOI: 10.1177/0961203308097570. View

Tonsawan P, Sawanyawisuth K . Clinical comparisons between previously diagnosed SLE and newly diagnosed SLE by kidney biopsy. Auto Immun Highlights. 2020; 11(1):18. PMC: 7709425. DOI: 10.1186/s13317-020-00140-2. View

Rittling S . Osteopontin in macrophage function. Expert Rev Mol Med. 2011; 13:e15. DOI: 10.1017/S1462399411001839. View

Uede T . Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int. 2011; 61(5):265-80. DOI: 10.1111/j.1440-1827.2011.02649.x. View

10.

Demir S, Gulhan B, Ozen S, Celegen K, Batu E, Tas N . Long-term renal survival of paediatric patients with lupus nephritis. Nephrol Dial Transplant. 2021; 37(6):1069-1077. DOI: 10.1093/ndt/gfab152. View

11.

Rianthavorn P, Buddhasri A . Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis. Pediatr Nephrol. 2015; 30(11):1969-76. DOI: 10.1007/s00467-015-3138-y. View

12.

Houssiau F, Vasconcelos C, DCruz D, Sebastiani G, de Ramon Garrido E, Danieli M . Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004; 50(12):3934-40. DOI: 10.1002/art.20666. View

13.

Hui M, Garner R, Rees F, Bavakunji R, Daniel P, Varughese S . Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus. 2013; 22(3):328-32. DOI: 10.1177/0961203312474084. View

14.

Wenderfer S, Ruth N, Brunner H . Advances in the care of children with lupus nephritis. Pediatr Res. 2016; 81(3):406-414. DOI: 10.1038/pr.2016.247. View

15.

Tsokos G . Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020; 21(6):605-614. PMC: 8135909. DOI: 10.1038/s41590-020-0677-6. View

16.

Kaul A, Gordon C, Crow M, Touma Z, Urowitz M, van Vollenhoven R . Systemic lupus erythematosus. Nat Rev Dis Primers. 2016; 2:16039. DOI: 10.1038/nrdp.2016.39. View

17.

Weening J, DAgati V, Schwartz M, Seshan S, Alpers C, Appel G . The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15(2):241-50. DOI: 10.1097/01.asn.0000108969.21691.5d. View

18.

Bajema I, Wilhelmus S, Alpers C, Bruijn J, Colvin R, Cook H . Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018; 93(4):789-796. DOI: 10.1016/j.kint.2017.11.023. View

19.

Triantafyllopoulou A, Franzke C, Seshan S, Perino G, Kalliolias G, Ramanujam M . Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A. 2010; 107(7):3012-7. PMC: 2840310. DOI: 10.1073/pnas.0914902107. View

20.

Groot N, de Graeff N, Marks S, Brogan P, Avcin T, Bader-Meunier B . European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017; 76(12):1965-1973. DOI: 10.1136/annrheumdis-2017-211898. View